All In MedTech

Device Trial Radar · NCT07717866

Trifecta Research Study

Trifecta Research Study - An Observational Study Evaluating the Impact of Ibogaine-Magnesium, 5-MeO-DMT, Magnetic e-Resonance Therapy, and Physiological Supplementation in Special Operations Forces Combat Veterans

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Actual

Start

Aug 1, 2022

Primary completion

Feb 1, 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Axial Therapeutic ResearchNot on our public-company list
Sponsor type
Industry
First posted
Jul 21, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder (PTSD) and traumatic brain injury-related cognitive symptoms among Special Operations Forces (SOF) combat veterans.

Conditions

  • PTSD - Post Traumatic Stress Disorder
  • Cognitive Dysfunction
  • Brain Injury
  • Depression - Major Depressive Disorder
  • Suicidal Ideation

Interventions

  • Magnetic e-Resonance Therapy (MeRT)Device

    MeRT, an electroencephalography (EEG)-guided Repetitive Transcranial Magnetic Stimulation therapy, is a non-invasive treatment that uses magnetic pulses to modulate neural networks of the brain, guided by an individual's brain patterns. MeRT is a neuromodulatory tool that has shown therapeutic efficacy in relation to decreasing severity of PTSD symptoms. There is preliminary data showing MeRT's therapeutic impact on depression and TBI-related cognitive impairment through promoting cortical excitability, modulating neurotransmission, and restoring neuroplasticity.

  • Ibogaine Hydrochloride with Magnesium SulfateDrug

    Ibogaine hydrochloride was administered orally. Ibogaine is an indole alkaloid that together with its metabolites interacts with mu opioid, kappa opioid, N-methyl-D-aspartate receptor (NMDA), and nicotinic acetylcholine receptors. Ibogaine has shown early signs of effectiveness as a rapid-acting treatment for a number of mental health disorders including PTSD and substance use disorder. Magnesium sulfate was administered intravenously prior to Ibogaine administration and orally each day.

  • 5-methoxy-N,N-dimethyltryptamineDrug

    5-MeO-DMT is administered by using a pipe to inhale a vapor that is produced by heating a canister containing a powder form of the substance. 5-MeO-DMT is a 5-HT-1A and 5-HT-2A agonist compound that has shown early signs of effectiveness in treating depression. Inhaled 5-MeO-DMT has a short duration of action, producing an intense, time-limited psychoactive state.

  • Physiological SupplementationDrug

    Physiological Supplementation describes a treatment program aimed at restoring healthy endocrine functioning, using supplements such as the following: Synthetic testosterone, Anastrozole, Gonadorelin, Vitamin and amino acid supplementation, Fish oil, Ipamorelin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PTSD Checklist for Diagnostic and Statistical Manual (DSM)-5 (PCL-5)Time frame: Up to 12 months follow up
  2. Medical Outcomes Study Cognitive Functioning Scale (MOS-CF)Time frame: Up to 12 months follow up
  3. Stroop Squared TaskTime frame: Up to 12 months follow-up

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Axial Therapeutic Research

    Northridge, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.